Microbicidal Light Treatment for Fungal & Bacterial Vaginosis

INVEST IN CERN CORPORATION TODAY!

Cern Corporation, Inc. is pre-revenue. We are developing and commercializing an effective, non-drug therapeutic treatment for fungal and bacterial vaginosis. The Cern Device™ uses low-level microbicidal light to mitigate pathogens associated with yeast and bacterial vaginosis in order to promote a healthy microbiome without the need for drugs. The small, device, similar in size to a tampon, is designed for use at home, as needed when needed, based on familiar symptoms. Development to date includes supportive work performed in vitro, ex vivo as well as in vivo (safety). Current work in microbiology expands our understanding of microbicidal light and it's effects on key pathogens associated with yeast and bacterial indications. Results from test data will be used to develop devices suitable for human use which will be validated in an early feasibility study focused on mechanism of action as efficacious in a human model. Cern has been granted utility and design patents along with trademarks. Cern has also received supportive 3rd part assessment specific to Freedom to Operate. Cern Corporation is currently in the pre-revenue and prototype/testing stages of development.
... Show more
This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
CERN Corporation

Reasons to Invest

  • We believe the Cern Device™ is the only patented Microbicidal Light device for the treatment of fungal, as well as bacterial vaginosis.
  • The global FemTech Market Size accounted for $46.3B in 2021 and is projected to grow an average CAGR of 13.3% from 2020 till 2025 (source).

  • Cern has received both utility and design patents along with independent review confirming Freedom to Operate. Our technology and application have been acknowledged by independent science and healthcare experts as what may be a significant break-through for women’s health.  






Overview


Cern hopes to enable healthier, empowered lives

As of July 2020, there are over 79 million women in the US between 15-49 (source Center for Disease Control/CDC). According to the CDC, over 21 million women are affected Bacterial Vaginosis (BV) (source). 


The Cern Device’ mechanism of action may prove efficacious for both yeast as well as bacterial infection which at times may occur simultaneously.


According to the CDC, over 21 million women are affected by Bacterial Vaginosis (BV) (source). Approximately 16% are considered symptomatic and are likely under a physician’s care Those that are asymptomatic remain at risk.  The Cern Device may have the ability to not only be used as a therapeutic but may be of value prophylactically as well. 


With regard to Fungal Vaginitis (Yeast Infection), the CDC reports an estimated 75% of women will have at least one episode of Vulvo Vaginal Candidiasis or VVC, 40%–45% will have two or more episodes. 10-20% of women with Vulvovaginal Candidiasis (yeast infection) can be classified as complicated VVC as well as recurrent which according to the CDC is four or more episodes per year, for which special diagnostic and therapeutic considerations are needed (source).



We are here to help the millions of women for whom drug based therapy may neither be effective nor appropriate and may be expanded to those who desire to avoid drug based treatment.


The Cern Device™ is designed to serve as an insertable vaginal device, enabling at-home treatment of fungal and bacterial vaginosis, without the need for oral or topical medications.  With that, we believe the Cern Device™ is the only patented Microbicidal Light device for these treatments, offering women a safe, convenient alternative for use at home when needed, as needed based on familiar symptoms.


*Images are computer generated demo versions. Product is still currently under development




The Problem


We believe we are serving a huge, unmet need

Vaginal infection can be painful, and overall uncomfortable. In fact, Bacterial Vaginosis is present in as many as 21 Million women, with about 16% of them being symptomatic under a doctor's care (source). The majority are undiagnosed, as symptoms may not be present or noticeable. The same technology is also relevant to fungal vaginitis or VVC. The CDC tracks recurrent fungal vaginitis, defined as 4 or more occurrences per year. CDC data indicates  as many as 12 Million women are recurrent under a doctor’s care, with perhaps 50% or more not responsive to treatment (source).  


Based on a National Science Foundation, I-Corp Discovery program conducted by Cern through the University of California at Irvine, Cern was made aware through interviews with physicians that many women do not wait until their fourth occurrence to seek treatment suggesting that CDC data on yeast infections, significant enough to warrant treatment by a doctor may be significantly under-reported and the potential market is significantly greater than statistics may suggest. 



The same device may have the ability to be used prophylactically and may be valuable to both women who seek to become pregnant so as to help avoid issues associated with bacterial vaginosis and pregnancy.  The Cern Device™ is also relevant to so many women who are immunocompromised where conventional drug based therapies may not be desired.


(source, source


With that, we believe the current standards of care are neither effective nor appropriate for all. In our view, current systemic antifungal, and antibiotic drugs deliver perhaps 2% of the medication to the targeted area. The remainder must be metabolized through the patient's organs. Not to mention, clinicians and patients alike are concerned with overuse of drugs - whose efficacy can be diminished as pathogens develop resistance (source, source, source).


(source, source, source)

The Solution


Introducing Microbicidal Light


The Cern Device™ is designed to be available as a prescription, as it is intended for use at home as needed based on recurrent symptoms - so as to avoid having to repeatedly visit a physician. Instead, the physician will be able to make remote consults, and monitor device usage and outcome. 



*Images are computer generated demo versions. Product is still currently under development


Shaped and sized similar to a tampon, the Cern Device™ can be inserted for 20-40 minutes - aiming to effectively control both bacterial and or fungal infection based on dosage. In a healthy microbiome, naturally occurring yeast and bacteria reside together in a symbiotic relationship. Infections tend to occur when an imbalance or dysbiosis occurs. 


The Cern Device™ will utilize specific wavelengths of light to disrupt the pathogen’s DNA - inhibiting the cell's ability to reproduce - and thus, will be able to restore the microbiome to a state of symbiosis.


*Images are computer generated demo versions. Product is still currently under development


The FDA is familiar with low-level microbicidal light and its mechanism of action, yet surprisingly, we don’t think they’ve seen products on the market today for this application. Cern believes this creates what many view as a new white space opportunity, which Cern has identified, received patents for, and is addressing.


*Images are computer generated demo versions. Product is still currently under development







The Market


We think Cern is more than an alternative 

In fact, we believe it can solve key issues in women’s health and potentially disrupt a large and growing FemTech market.


The global FemTech Market Size accounted for $46.3 Billion in 2021 and is projected to grow an average CAGR of 13.3% from 2020 till 2025. That means it could reach $79.4 billion by 2030 (source).

(source, source)


To us, our key differentiators when it comes to market penetration is that our device will potentially be: 


  • A Non-Drug, avoiding negative drug interactions
  • Science-Based Reactive Oxygen Species (“ROS”)
  • A combatent for “Superbugs”
  • Potential for use pre-pregnancy
  • May address a significant need amongst  immunocompromised
  • Platform for Telemedicine

Our Traction


On track to helping women everywhere


Cern is patented having received both utility and design patents in the US with international patents now filed with an ever-expanding IP portfolio evolving. Cern has also received independent review confirming Freedom to Operate and is being acknowledged as what may be a significant break-through for women’s health.  


*Images are computer generated demo versions. Product is still currently under development


Here’s a look at some of our other milestones:


  • Established a Board of Directors with prominent leaders in healthcare
  • Compelling Approach: Selected to present at the International Society for the Study of Vulvovaginal Disease (ISSVD) XXVI World Congress (source)
  • Patented (Utility and Design) with International Patents Filed
  • Freedom to Operate indicates Cern may be unique and operate unfettered
  • Trademarks with additional patents pending
  • LA BioStart Life Science Development Program
  • FDA Pre-Submission (Denovo 510K)
  • Independent Market Assessment: Innovation Institute 
  • Hospital/Healthcare Provider Interest
  • Corporate Interest from organizations such as Medtronic / Bayer AG / J&J 
  • In-vitro: OakCrest Inst. of Science (Los Angeles)
  • In-vivo “Safety” Ovine model
  • Univ of Georgia review of Cytology
  • Ex-vivo Cytotoxicity/Dose Response: LSU School of Medicine
  • National Science Foundation / UC Irvine: I-Corp Customer Discovery validating both need and interest of both clinicians (prescribers) and women (user)








Why Invest


We think women’s health should be more inclusive, and accessible


At Cern, we feel we are unique in our approach of:


  • Leveraging low level microbicidal light in the visible spectrum
  • Potentially mitigating pathogens associated with fungal and bacterial vaginosis through the mechanism of reactive oxygen species
  • All done without drugs


Plus, we feel that the interest shown by both users and clinicians indicates there is a significant ready market of those interested in using the device, as well as those interested in prescribing the device. 


*Images are computer generated demo versions. Product is still currently under development


Overall, we believe there isn’t another product on the market like the Cern Device™, especially one that’s been filed and granted extensive IP. 


Join us, and invest in what we believe will be a revolution in women’s health!




Bold (⌘B)
Code View

ABOUT

HEADQUARTERS
31891 Via Oso
Coto de Caza, CA 92679
VALUATION
$12.01M

Cern Corporation, Inc. is pre-revenue. We are developing and commercializing an effective, non-drug therapeutic treatment for fungal and bacterial vaginosis. The Cern Device™ uses low-level microbicidal light to mitigate pathogens associated with yeast and bacterial vaginosis in order to promote a healthy microbiome without the need for drugs. The small, device, similar in size to a tampon, is designed for use at home, as needed when needed, based on familiar symptoms. Development to date includes supportive work performed in vitro, ex vivo as well as in vivo (safety). Current work in microbiology expands our understanding of microbicidal light and it's effects on key pathogens associated with yeast and bacterial indications. Results from test data will be used to develop devices suitable for human use which will be validated in an early feasibility study focused on mechanism of action as efficacious in a human model. Cern has been granted utility and design patents along with trademarks. Cern has also received supportive 3rd part assessment specific to Freedom to Operate. Cern Corporation is currently in the pre-revenue and prototype/testing stages of development.

TEAM

Dr. David C. Lagrew

Dr. David C. Lagrew

Board of Directors

Chief of Service, Maternal Fetal Medicine at Hoag Hospital, Newport Beach, California. Past positions include Executive Medical Director, Women's Services at Providence St. Joseph Health where he manages development of the Ministry's Centers of Excellence and regional Clinical Institute of Women's Health within St. Joseph’s/Providence Health. David’s background also includes extensive executive experience having held the position of Medical Director at Long Beach Memorial as well as Medical Director, Women’s Services at Saddleback Memorial Medical Center prior to his appointment as Executive Director, Women’s Services at St. Joseph’s. David has recently retired from over 35 years of clinical practice and is regarded as a thought leader within the industry. David works part-time on Cern (2 hours/week).

Dr. Melanie Santos, MD FACOG, FPMRS

Dr. Melanie Santos, MD FACOG, FPMRS

Chief Medical Officer

Dr. Santos is a Urogynecology & Reconstructive Pelvic Surgery Specialist in Fullerton, CA with over 17 years of experience in the medical field. Dr. Santos graduated from Albert Einstein College of Medicine of Yeshiva University Medical School in 2004. She completed her residency in Obstetrics and Gynecology at Stanford University, followed by fellowship training for Pelvic Reconstructive Surgery at Emory University. She is affiliated with St. Jude Medical Center, within the Providence St. Joseph Healthcare system. Dr. Santos is Medical Director of Pelvic Health at St. Jude and on executive and national advisory boards for the Providence St. Joseph Women and Children's Institute, while also performing clinical work at St. Jude Heritage Women’s Center in Orange County California. Dr. Santos has considerable experience working in the medical device and pharma area as she consults to various entities and is a key-note speaker internal to Providence Health being responsible for communications with GYN related practitioners within the organization. She is also an advocate for women in medicine, developing the Women Physicans Group at her hospital as well as an annual summit for women in healthcare. Melanie works part-time on Cern (5 hours/week on Cern).

Hyunsook Park, PhD

Hyunsook Park, PhD

Director of Microbiology

Dr. Park is a Professor of Microbiology at California State University Los Angeles and has over twenty years of research experience on fungal pathogenesis. As a first-generation immigrant and a woman scientist, her research is naturally geared toward the direction of making a profound impact on improving women’s health. Using C. albicans as a model fungal pathogen, Dr. Park studied how human fungus recognizes the host environmental changes and initiates infection from a part of the normal microbiome. She also studied developing a combination therapy to overcome the limitation of the current antifungal agents to treat oral and vaginal candidiasis.Positions and Education: 2008 – Current, California State University, Los Angeles, 2002 – 2007, Fungal Pathogenesis Research Group at Harbor-UCLA Medical Center, 1998-2002. Ph.D. in Microbiology at Ewha Womans University, Korea. Hyunsook works part-time on Cern (20 hours/week on Cern).

Todd Peterson, PhD

Todd Peterson, PhD

Chief Science Advsior

Dr. Todd Peterson is the Founder and Principal of GenApex Bio, a life sciences advisory, investment, and board practice company based in Coronado, California. With over 35 years across academic research and industrial R&D, spanning molecular genetics, genomics, cell biology and synthetic biology engineering, his experience encompasses biotechnology, clinical diagnostics, life science research tools, drug discovery and industrial biotechnology markets, products, and technologies. Prior to GenApex Bio, Dr. Peterson was Chief Scientific Officer at the Allen Institute comprising foundational and applied research programs across its Brain Science, Cell Science, Immunology Institutes, and the Paul G. Allen Frontiers Group. Prior to the Allen Institute, Dr. Peterson was Chief Technology Officer at Synthetic Genomics (SGI) where he led an integrated team of scientists, engineers and informaticians to engineer diverse complex living systems. Before joining SGI, he led Synthetic Biology, Cloning and Protein Expression and Genomics R&D at Invitrogen/Life Technologies (now ThermoFisher), a global leader in life science research tools. Dr. Peterson has held industrial R&D leadership and bench scientist positions with increasing responsibilities at Genicon Sciences, Trega Biosciences, Hybritech, Gen-Probe and Immulok, focusing on technology development and product commercialization. Dr. Peterson was a postdoctoral fellow at the Max Planck Institute in Cologne, Germany, received his Ph.D. in Microbiology at the University of Southern California School of Medicine, and received his M.A. in Biological Sciences and his B.A. in Molecular Biology and Biochemistry from the University of California, Santa Barbara. Todd works part-time on Cern (5 hours/week).

Dr. Jack Sobel

Dr. Jack Sobel

Key Advisor

Dr. Sobel is a consulting Physician, Clinical Advisor, and one of the world’s foremost authorities on infectious diseases of the GYN tract. Dr. Sobel is a widely published and strongly funded physician-researcher. He has been involved in basic science, translational and clinical research since the inception of his Infectious Diseases Research Fellowship in 1976 at the NIH Laboratory of Clinical Investigation. He has served as a consultant for the U.S. Centers for Disease Control and Prevention’s special committee for recommending guidelines for the treatment of sexually transmitted disease. He has served as President of the Michigan Infectious Diseases Society from 1997 to 1999, a Member of the Infectious Diseases Society of America, and the National State President’s Committee and the Infectious Diseases Society of America, Practice Guidelines Committee. Jack works part-time on Cern (1 hour/week).

Vern Roohk, PhD

Vern Roohk, PhD

PhD, Physiology

Vern Roohk received his PhD in Physiology and Biochemistry from UC Davis in 1971 and did post-doctoral stints in bioengineering at USC and UCLA over the next few years. He has clinical experience as an ECMO (Extracorporeal Membrane Oxygenation) team member and lab supervisor with the original NIH-funded life-support team at UCI from the mid 1970s. Since then Dr. Roohk has served as lab director and/or IACUC chair for a number of both university and private pre-clinical testing facilities. Dr. Roohk has spent over 50 years in physiology associated with the development and testing of medical devices. Dr. Roohk co-founded American ImmunoTech, LLC, and Vestara in Costa Mesa, CA, which conducted sepsis research utilizing ultraviolet technology in an extracorporeal circuit. Dr Roohk is a recognized expert in Animal Physiology, and in vivo testing. Vern works part-time on Cern (2 hours/week).

Gregg A. Klang

Gregg A. Klang

CEO, President and Founder

Founder/Inventor of the Cern Device™. Gregg’s background is principally in business and marketing, with most of his career in technical sales and marketing for a Fortune 50 organization. Gregg has senior management experience, an extensive background in global sales and account management, and extensive training through the Boston Consulting Group. His interest in life sciences has generated multiple patents in the medical device space. In the summer of 2019, Cern Corp. was nominated to participate in the LA-BioStart program for CEOs who are bringing novel and disruptive technologies within the life sciences vertical to market. Education: MBA Pepperdine University, BA Economics University California, Irvine. Greg works full-time Cern.

Annette M. Walker

Annette M. Walker

Board of Directors

Annette’s current position is President, City of Hope Orange County. An experienced healthcare executive with decades of experience that includes broad roles such as the President of Strategy for Providence St. Joseph Health, the third largest provider organization in the country. Annette has twice been recognized as one of the “Top 100” people in US Healthcare Modern Healthcare, the industry's leading trade journal. In her position at City of Hope, she is responsible for the development of an academic campus that will be Orange County, California's most advanced cancer prevention, treatment and research OP center and hospital. Annette is a solutions architect and nationally recognized strategist, thought leader and author/keynote speaker on transforming the health care industry.

TERMS

CERN Corporation
Overview
PRICE PER SHARE
$0.80
DEADLINE
Dec 29, 2022
VALUATION
$12.01M
AMOUNT RAISED
$335,300.32
Breakdown
MIN INVESTMENT
$500.00
MAX INVESTMENT
$1,070,000.00
MIN NUMBER OF SHARES OFFERED
12,500
OFFERING TYPE
Equity
ASSET TYPE
COMMON
SHARES OFFERED
Common Stock
MAX NUMBER OF SHARES OFFERED
1,337,500

Maximum Number of Shares Offered subject to adjustment for bonus shares


Company

:

Cern Corporation

Corporate Address

:

31891 Via Oso, Coto de Caza, CA 92679

Offering Minimum

:

$10,000.00

Offering Maximum

:

$1,070,000.00

Minimum Investment Amount

(per investor)

:

$500.00











Terms


Offering Type

:

Equity

Security Name

:

Common Stock

Minimum Number of Shares Offered

:

12,500

Maximum Number of Shares Offered

:

1,337,500

Price per Share

:

$0.80

Pre-Money Valuation

:

$12,006,620.00











*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.

Voting Rights of Securities Sold in this Offering

Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

Investment Incentives and Bonuses*

Time-Based:

Friends and Family Early Birds

Invest within 2 weeks + 72 hours and receive 10% bonus shares.

Early Bird Bonus

Invest within the next two weeks and receive 5% bonus shares.

Amount-Based:

$5,000+ | Tier 1

Invest $5,000+ and receive 3% bonus shares

 $10,000+ | Tier 2

Invest $10,000+ and receive 6% bonus shares

$20,000+ | Tier 3

Invest $20,000+ and receive 10% bonus shares + personal Zoom call with founder/CEO

Loyalty Bonus:

A Loyalty Bonus will be offered to Friends and Family for 5% bonus shares. 

*All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

CERN Corporation will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $0.80 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $80. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus in addition to the aforementioned bonus.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments. Salary payments made to one’s self, a friend or relative.

ALL UPDATES

12.01.22

National Science Foundation, I-Corp Customer Discovery: What do Women think about The Cern Device and Current Care?

                                           

            Women (Users): > 40 Interviews

• Desire for Less Invasive, Non-Drug Treatments: 100% agree.  Significant interest in avoiding drug treatments

• Drug Avoidance Of Significant Interest: Why? Negative drug interactions, Side effects

• 30-60 Min/Day For 1 To 3 Days Is Acceptable: Use of The Cern Device for successive days is acceptable

• Ability to be Ambulatory Is Important: The device, once inserted would not hamper movement.

• Ability to Use During Menses: Significant correlation between menses and indication for use

• Education will be Key/Interest as “Preventative”: The ability to upload data, patient profile to find correlations may be significant toward avoidance of issues


"The above statements are representative of interviews conducted by the Cern Corporation team and not indicative medical advice or published research."

11.28.22

National Science Foundation, I-Corp Customer Discovery: What do Physicians think about The Cern Device and Current Care?


                                 


Physician Perspective:


• Recurrent Patients are “Frustrated” w Drug Base Standard of Care

• We Treat Women w <3 Infections/Year. The CDC Under Reports Tracking only 4+: 100% (Market is larger than CDC numbers disclose)

• Would Prescribe As Alternative To Drugs: 100% (Factors Include Patients History, Drug Tolerance, Interest in Drug Avoidance)

• Clinical Data is Key/“Early Adopters” Based on Data & “Low” Risk: 90% (90% would use The Cern Device ASAP)

• Drugs Proving Insufficient: 100% (Pathogen resistance to drugs is on the increase)

• “Too much time is taken up by routine yeast or bacterial infection visits”: 70% 

• Difficult to Diagnose: 60% (Cern treats Both Yeast & Bacterial which often occur together)

• Interest in Platform for Data / Epidemiology: 100% (Data is key to understanding)

• Capitated Reimbursement, Cern Lowers Care Costs 100% (At home therapy as needed, when needed)


"The above statements are representative of interviews conducted by the Cern Corporation team and not indicative medical advice or published research."

11.04.22

Cern's average investment is close to $10,000! Why? "Unmet Need" / "White Space"...Creates a Unique Opportunity

Thank you all for the tremendous support!  Cern's average investment is close to $10,000 per investor!  There are a number of people who have followed our progress. Start Engine has afforded them the mechanism to be directly involved.

The reasons are straight forward...

Significant Unmet Need: Specifically, the need for an effective, non-drug solution based on the scientific principles of low level microbicidal light to mitigate key pathogen associated with yeast, as well as bacterial vaginosis.  While these are separate medical indications, treated in different manners,  the Cern Device' mechanism of action has yielded supporting data showing an ability to effectively mitigate key pathogen associated with both indications....without drugs.

"Yes, but what about the good stuff?": A common question has been "what are the effects of your treatment on key, beneficial, native flora such as lactobacillus" critical to a healthy GYN microbiome)?  The answer is, "not much".  Lactobacillus has been shown to require much larger dosages of microbicidal light as compared to "key" detrimental species such as Candida Albicans (yeast) and Gardnerella Vaginalis (bacteria). This means we have the ability to mitigate the "bad" without harming the "good".  This is knows as a "therapeutic window".

Validation of Need: Independent validation by organizations such as The Innovation Institute (JV of Bon Secours, Cleveland Clinic, St. Joe's), Google's Singularity Institute as well as globally renowned key opinion leaders (KOL's) who deal with this daily, all validate the need for an effective non-drug therapy.

Population: Drug based standards of care are not effective, nor appropriate for a significant portion of the population.  Estimates of US population under physician care yield in excess of 9M women based on conservative CDC data. If Cern captures 10% or 1 in every 10 women seeing a physician for either indication, Cern sales have the ability to exceed $180M/Year.  Our numbers expand significantly when you consider women who simply want to avoid drugs. 

IP Position: Cern has received patents including both Utility and Design patents! These are actual "patents" as opposed to "patent pending".  We have more in process! 

Freedom to Operate:  Having patents is great, having an independent assessment confirming "Freedom to Operate" is also very significant. This means we doing something unique, not considered an encroachment on "others" IP.

Join our incredible group of investors and invest now!

Thank you,  Gregg

Gregg A. Klang - Cern Corporation, CEO


10.24.22

Insider Investment Notice

We’re pleased to see our community come in and invest in Cern Corporation, Inc.. Thus far, our Insiders have invested a total of $45,000 into the offering.  We hope you join as well! 

Please refer to the Company’s offering materials for further information and refer to the Company’s Risk Factors.

If you have questions or concerns regarding what is believed to be an insider investor please review the help article HERE.

 Please let me know If you have any questions or concerns.  

 Best,

 Gregg A. Klang - Cern Corporation, CEO

10.21.22

What if?

“What if” there was an effective, non-drug treatment for yeast and bacterial vaginosis which may: 

  • enable you to live a healthier life without drugs?
  • enable you to avoid use of toxic, systemic drugs?
  • help to avoid negative drug interactions by not interfering with your prescriptions?
  • be effective for both fungal (yeast) vaginitis & bacterial vaginosis?
  • help to avoid use of messy, inconvenient “crèmes”?
  • be appropriate for those who may be immuno-compromised?
  • be appropriate for use during pregnancy?
  • effectively deal with both drug resistant yeast & bacteria?
  • avoid harm to lactobacillus, one of the key components of a healthy microbiome?
  • helps prevent infection and STD’s?
  • be used at home when needed/as needed, based on familiar, recurrent symptoms?
  • enable user feedback for better understanding of how to treat these indications through AI?
  • be supported by some of the most prominent clinicians and researchers in the field?
  • had, as its mechanism of action, valid, scientific principles of microbicidal light?

Yep…That’s what we are doing!   

And you can be part of the story.  Help bring The Cern Device to market!   Invest now!


10.19.22

Letter of Support to Cern Corporation for the Development of a Non-Drug Treatment for Yeast & Bacterial Vaginosis


I thought I'd share an example (one of many), respective of the feedback and interest Cern has received for our development of an effective, science-based, non-drug treatment for yeast and bacterial vaginosis.  

Thank you for all.  

Gregg A. Klang

CEO Cern Corporation

______________________________________________________________________________________________________________

10.12.22

Women Devoted to Science and Health, Addressing a Significant Global Issue



Three Women, a leader recognized as "One of the Top 100 People in Healthcare", a nationally recognized MD/Urogynecologist, and a renowned Ph.D. in Microbiology. Each significant in their fields, joining forces to develop and bring to market, a new treatment, outside conventional thinking, while using well understood tenants of science in a novel, disruptive manner. Why?  Because new treatments are essential to combat evolving yeast and bacterial issues in women.  Meet Annette M. Walker,  Hyunsook Park, PhD and Dr. Melanie Santos, MD, and get their personal perspective.

Dr. Melanie Santos, MD Urogynecologist - Chief Medical Officer

I'm excited to contribute and help evolve a critical, novel and much needed therapy through my involvement with Cern Corp.. As a practicing Uro-Gynecologist, I'm all to aware of the struggles women face with recurrent vaginal infections, seeing these women on a daily basis in my practice. Treating women weekly with our current therapies, which are really only limited to medications, which can then cause additional issues, including adverse effects and in some cases additional infections, has a been a long time frustration. To be involved with an option which could truly revolutionize our approach to women’s health, well that is a game changer.”


Hyunsook Park, Ph.D. – Director of Microbiology

I have devoted over twenty years of my life to research and evolution of treatment of vaginal infection. Specifically, the study of host-pathogen interaction, leading to dynamic genome expression change in both host and fungal aspects. I also have applied these studies to understand molecular mechanisms of disease development and to develop antifungal strategies. I was intrigued with Cern’s approach, something different, which uses sound, well understood, scientific principles to mitigate vaginal infection without the need for drugs, while at the same time, avoiding development of drug resistant pathogen as well as addressing issues with complex drug interactions which arise too frequently for women taking multiple prescriptions. continue to suffer throughout their life with recurring infections.


Annette M. Walker - Board of Directors

I've spent my career working to improve patient outcome by focusing on the creation and management of environments which deliver state-of-the-art healthcare for all in need. I’m honored to be involved with Cern Corporation as we work to develop products which are not only effective, and affordable, but address a significant “Unmet Need” for so many women, so as to improve quality of life.

10.10.22

Cern Corporation selected by the LARTA Institute, Los Angeles CA to participate in their Heal.LA BioScience & Healthcare Accelerator

Said Gregg Klang, Cern Corporation's Founder and CEO, "We are extremely pleased to be selected by the LARTA Institute (LARTA.org) to be involved in their Heal.LA program for LifeSciences.  The depth of resources LARTA makes available are tremendous.  To have  so many people, significant  in the field of Life Sciences interested, willing to be involved and assist Cern Corp. as we move forward, is an honor and privilege". 

10.06.22

Cern Corporation selected to present at Bioscience LA to be held at The Lundquist Institute in Los Angeles.

Said Gregg Klang, Cern Corporation's CEO, "It's tremendous to receive these opportunities to speak and get the word out regarding our novel treatment for yeast and bacterial vaginosis, without drugs".  "It seems as though we've identified a significant unmet need as there are so many women for whom drug based therapies are neither effective, appropriate or desired".  This is a top notch program comprised of significant organizations such as The Lundquist Institute, UCLA, The LARTA Institute, BioCom California as well as BioScience LA.  Thank you to all"

About The Lundquist Institute:  The Lundquist Institute for Biomedical Innovation, is delighted to partner with BioscienceLA, the Larta Institute, Biocom California, and UCLA TDG to bring you captivating biomedical startup innovations and deep industry insights.

The Innovation Showcase was created to promote and share bioscience start-ups and early stage technologies. By inviting a targeted audience of entrepreneurs, mentors, investors, trade organizations, technology transfer experts, life science industry professionals, and service providers, the Showcase provides an intimate environment to facilitate business discussions and meaningful networking. 

10.04.22

Cern Corporation - Recognized by Southern California's Octane Accelerator as "Ones to Watch"

150 Companies were interviewed, four established companies were recognized in various fields.  The interviewers believed Cern, with our work in women's health, the development of a non-drug treatment using microbicidal light for mitigation of yeast and bacterial vaginosis, to be so compelling that a new category was formed..."Ones to Watch".

Gregg Klang, Cern's CEO and Founder was in attendance along with Chief Medical Officer,  Dr. Melanie Santos  as well as board member Annette M. Walker (President, City of Hope).  Said Gregg: "I'm so proud to be aligned with Melanie and Annette, both of whom are recognized leaders in their field.  Just more validation that what we are doing is significant for so many."

Thank you Carol, Rita and all the others at Octane who contributed to make this event so terrific. Gregg














Owners bonus
Stack Owner's Bonus & Rewards!

Members get an extra 10% shares in addition to rewards below!

REWARDS

Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into CERN Corporation.

$500.00

StartEngine Owner’s Bonus

This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.

$5,000.00

Tier 1

Invest $5,000+ and receive 3% bonus shares

$10,000.00

Tier 2

Invest $10,000+ and receive 6% bonus shares

$20,000.00

Tier 3

Invest $20,000+ and receive 10% bonus shares + personal Zoom call with founder/CEO

JOIN THE DISCUSSION













0/2500

HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

WHY STARTENGINE?

REWARDSWe want you to succeed and get the most out of your money by offering rewards and memberships!
SECUREYour info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTSInvest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team

Careers

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.


www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.


Investment opportunities posted and accessible through the site are of three types:


1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.


Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.


By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.


Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.


California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.


StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.